USA flag logo/image

An Official Website of the United States Government

Investigation of CytoSorb cytokine and myoglobin removal in the treatment of…

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
A2-5174
Solicitation Year:
2011
Solicitation Topic Code:
A11-105
Solicitation Number:
2011.2
Small Business Information
CYTOSORBENTS, INC.
7 DEER PARK DRIVE, SUITE K MONMOUTH JUNCTION, NJ 99999-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: Investigation of CytoSorb cytokine and myoglobin removal in the treatment of trauma and burn injury
Agency: DOD
Contract: W81XWH-12-C-0038
Award Amount: $1,000,000.00
 

Abstract:

Trauma and burn injuries are leading causes of military casualties and need more effective treatments. They are frequently associated with a severe systemic inflammatory response syndrome, triggered by tissue damage, cytokine and inflammatory mediator release, ischemia-reperfusion injury, and others, as well as complications such as hemorrhage and rhabdomyolysis that can cause multiple organ dysfunction syndrome (MODS) and multi-organ failure (MOF). Organ failure significantly increases the risk of morbidity and mortality in wounded warfighters. Despite this, there have been few advances in treating these underlying causes of organ injury. In this Phase II SBIR proposal, CytoSorbents plans to demonstrate the broad utility of blood purification, using an advanced, biocompatible, porous polymer sorbent, to prevent or treat organ failure in both trauma and burn injury. Building upon work accomplished in Phase I, CytoSorbents will test a portable, robust, and logistically-friendly blood purification system that combines a state-of-the-art battery-powered blood pump with CytoSorbents"sorbent bead technology, that can be easily stockpiled and used in far-forward medical facilities. This blood purification system will be tested in two porcine models of trauma/rhabdomyolysis and burn/inhalation injury to reduce excessive cytokines, myoglobin and other inflammatory mediators in blood, with the goal of preventing or treating organ failure.

Principal Investigator:

Phillip Chan
CEO
(732) 329-8885
pchan@cytosorbents.com

Business Contact:

Humayra Ali
Senior Business Analyst
(732) 329-8885
humayraa@cytosorbents.com
Small Business Information at Submission:

CytoSorbents Inc.
7 Deer Park Drive, Suite K Monmouth Junction, NJ -

EIN/Tax ID: 204496406
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No